LifeSci Capital analyst Charles Zhu has maintained their bullish stance on MRUS stock, giving a Buy rating on May 5.
Charles Zhu has given his Buy rating due to a combination of factors including Merus’s promising developments in their clinical trials and strategic management decisions. The company is actively progressing with its Phase 2 and Phase 3 trials for petosemtamab in head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC), which show strong potential based on clinical activity metrics such as overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Management’s confidence in the ongoing trials and their strategic focus on activating multiple sites globally to enhance enrollment rates further supports the positive outlook.
Additionally, Merus’s financial health appears stable, with a cash runway of approximately three years, which provides a solid foundation for continued research and development efforts. The company’s ability to adapt and respond to competitive dynamics, such as those posed by amivantamab, and their strategic insights into patient population heterogeneity, also contribute to the Buy rating. Overall, these factors combined suggest a promising growth trajectory for Merus, justifying the positive recommendation.